Duobrii in Combination With Biologics

Clinical Trial ID: NCT04119102

Description

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks


Criteria

Inclusion Criteria: 1. Male or female adult ≥ 18 years of age; 2. Diagnosis of chronic plaque-type 3. Psoriasis affecting 2%-10% BSA 4. Patient is being treated with biologic therapy for a minimum of 24 weeks 5. Able and willing to give written informed consent prior to performance of any study-related procedures Exclusion Criteria: 1. Psoriasis affecting ˂2% or >10% BSA 2. Patient not receiving a biologic agent, or receiving biologic agent <24weeks 3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit. 4. Has previously used DUOBRII

  • Start Date

    2019-10-01

  • Last Updated

    2019-10-04

  • Sponsor

    Ortho Dermatologics

  • Condition Name

    Psoriasis

Learn about this trial.

Check the eligibility requirements, study details, and more.

Related Trials

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.